Effects of lead on Epidermal wound Contraction and serum biochemistry in West African dwarf goats; Urinary Iodine levels determined by inductive Couple Plazma Mass Spectrometry in the State of Kuwait.

E3 Journal of Medical Research

E3 Journal of Medical Research Vol. 1 (1) pp. 006-013, February 2012; © E3 Journals; ISSN 2276-9900

XRCC2 and XRRC4 Gene Polymorphism and Risk of Gliomas

Custódio A.C.1 * , Almeida L.O1 , Pinto G.R1,3 , Santos M.J2 , Almeida J.R.W2 , Clara C.A2 , Rey J.A4 , Casartelli C1
1 Departamento de Genética, Faculdade de Medicina de Ribeirão Preto, Laboratório de Oncogenética, Universidade de São Paulo, Ribeirão Preto, SP, Brasil
2 Fundação Pio XII, Hospital de Câncer de Barretos, Barretos, SP, Brasil
3 Laboratório de Genética Humana e Biologia Molecular,Universidade Federal do Piauí, Parnaíba, PI, Brasil
4 Departamento de Cirurgia Experimental, Laboratótio de Oncogenética Molecular,Hospital Universitário “La Paz”, Madrid, Espanha
*Corresponding Author E-mail: alinecadurin@yahoo.com.br
Accepted 8 February 2012


XRCC genes (X-ray cross complementing group) were found mainly for their roles in protecting mammalian cells against damage caused by ionizing radiation. Studies determined that these genes are important in the genetic stability of DNA. Although the loss of some of these genes does not necessarily confer high levels of sensitivity to radiation, they have been found to represent important components of various pathways of DNA repair. To ensure the integrity of the genome, a complex system of DNA repair was developed. The gene XRCC2 (X – ray cross complementing group 2) is required to repair damage caused when recombination occurs between homologous chromosomes. The gene XRCC4 (X – ray cross complemeting group 4) played an important role in repairing double-strand breaks in DNA at the ends of homologous chromosomes. PCR-RFLP in 80 astrocytomas and glioblastomas brain tumor sample. Patients who had the allele H of the XRCC2 Arg188His and allele T of the XRCC4 G1394T polymorphism had an increased risk of tumor development (OR=13,33; confidence interval at 95%, 95% CI = 6,22 – 28,57; p<0,001) and (OR=6,45; confidence interval at 95%, 95% CI = 2,90 – 14,33; p<0,001). We suggest that XRCC2 Arg188His and XRCC4 G1394T polymorphisms are involved in susceptibility for developing gliomas.

Keywords: Polymorphism; XRCC2; XRCC4; Astrocytoma; Glioblastoma

[Download Article - PDF]